Navigation Links
Opsona Therapeutics Closes EUR18M Funding
Date:2/18/2009

DUBLIN, Ireland, February 18 /PRNewswire/ -- Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, today announced the completion of an EUR18M ($23M) Series B financing round which will enable it to expand both at an operational and clinical level. Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences all participated in the funding.

Proceeds will support the advancement of Opsona's clinical trials targeting inflammatory diseases, such as rheumatoid arthritis, lupus and transplantation. As a part of the financing, Opsona Therapeutics also announced the addition of Florent Gros, managing director at Novartis Venture Fund, and Dr. Manus Rogan, managing partner at Fountain Healthcare Partners, to the Board of Directors. Opsona expects to make a number of other key appointments in the corporate and clinical areas in the coming months.

Commenting on the announcement, Dr Mark Heffernan, Chief Executive Officer of Opsona Therapeutics, said: "Completion of this financing represents a significant milestone in the transition of Opsona into a product-focused company delivering key clinical development milestones. With the endorsement of our existing and new investors, including the Novartis Venture Fund, Fountain Healthcare Partners and Seroba Kernel Life Sciences. Opsona is positioned to deliver on proof of concept studies in patients by targeting inflammatory diseases through the innate immune system, with our ultimate aim being to uncover innovative therapies that combat diseases with significant unmet medical need."

Opsona is developing biopharmaceutical and small molecule products which modulate the innate immune system, which is the key trigger in the inflammation cascade in many autoimmune and inflammatory diseases. Opsona's lead product, a fully hum
'/>"/>

SOURCE Opsona Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and CEO, will provide an update on the progress of ... of the company,s business strategy at 1:30pm ET on Monday, ... The conference is being held in New York, ... live and may be accessed via a link on the ...
(Date:5/26/2015)... 2015 Global Stem Cells Group ... for the company’s first cellular and regenerative medicine symposium ... full day, hands-on stem cell training class Oct. 10. ... Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona. ... interest in regenerative medicine and recent advances in cellular ...
(Date:5/26/2015)... , May 26, 2015 Pharmaco-Kinesis Corporation (PKC) ... recently convened at Shutters on the Beach in ... development status of the Company,s innovative Metronomic Biofeedback Pump ... locally deliver chemotherapy over time to a target site ... capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that all ... 2014 were exercised prior to their expiry on June ... of $11.7 million. "We thank our shareholders ... President and CEO of Asterias. "This exercise of warrants ...
Breaking Biology Technology:Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... researchers and a colleague from India unveiled a new ... was presented at the 63rd annual meeting of the ... The cancer treatment uses hyperthermia to elevate the ... tissue at a lower degree of body heat. The ...
... clocks adjust to having less sunlight in the winter could help ... Scientists studying the daily activity cycle in plants known ... enables the plant,s genes to respond to the times of dawn ... in between. This system helps the plant to reset its ...
... engineering researchers in the University of Minnesota,s College of ... at higher temperatures may be an effective tool in ... solid waste to 130 degrees Fahrenheit (55 degrees Celsius) ... antibiotic resistance. These genes are used by bacteria to ...
Cached Biology News:Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative 2University of Minnesota engineering researcher finds new way to fight antibiotic-resistant bacteria 2
... The Neural Stem Cell Expansion Kit - ... vitro neural stem cell expansion as neurospheres ... a specially formulated N-2 Plus Media Supplement, which ... (Johe, K.K. et al . (1996) Genes ...
... thymus Description: Topoisomerase I relaxes both ... breakage and rejoining of phosphodiester bonds (1,2) . ... to be differentiated by a single nucleotide pair ... active in the absence of Mn 2+ ...
... I, Wild Type Liquid. In 100 ... 200 µM EDTA, 20% glycerol, pH 7.9. AVOID ... is a monomeric protein of 765 amino acids ... relaxation of both positive and negative supercoiled DNAs ...
DNA polymerase I, large fragment...
Biology Products: